Destabilized GFP (dGFP) protein for mRNA stability studies
Destabilized GFP (dGFP) is a fluorescent reporter engineered for rapid proteasomal turnover. Unlike wild-type EGFP, which is highly stable (half-life >24 h) and unsuitable for tracking dynamic changes in mRNA stability and expression, dEGFP was generated by fusing amino acids 422–461 of the degradation domain of mouse ornithine decarboxylase (MODC) to the C-terminus of EGFP. This fusion targets the protein to the proteasome, reducing its fluorescence half-life to approximately 2 h. The shortened half-life allows dGFP to faithfully track rapid, transient changes in transcriptional activity that would otherwise remain undetected with conventional stable reporters.
Applications:
1) Li, X., Zhao, X., Fang, Y., Jiang, X., Duong, T., Fan, C., Huang, C.-C., & Kain, S. R. (1998). Generation of Destabilized Green Fluorescent Protein as a Transcription Reporter. Journal of Biological Chemistry, 273(52), 34970–34975
2) Kitsera, N., Khobta, A., & Epe, B. (2007). Destabilized green fluorescent protein detects rapid removal of transcription blocks after genotoxic exposure. BioTechniques, 43(2), 222–227
3) Houser, J. R., Ford, E., Bhatt, D. L., Ko, M. S. H., & Bhatt, D. L. (2005). Use of mRNA- and protein-destabilizing elements to develop a highly responsive reporter system. Nucleic Acids Research, 33(3), e27
4) GenBank accession: QSL83276.1
Cisterna's off-the-shelf RNAs are validated and ready to order through our quick quote system. Simply follow these steps: Step 1 (Find your RNA) If you already know what you need, select your desired RNA directly from the main page. If you'd like to learn more first, browse by category, click on the RNA name to view its product page, and explore usage examples and references before ordering. Step 2 (Add to Cart) Choose your preferred 'Quality', 'Amount', and 'Quantity', then click 'Add to Cart'. Repeat for any additional items. Step 3 (Get a Quote) When all items are in your cart, click 'Get a Quote'. Fill in your name, professional email, and academic or business address. Please note that personal email addresses and home addresses will not be accepted. Step 4 (Save your Quote) Once your information is complete, you can download your quote as a PDF for your records. Step 5 (Checkout) Click 'Continue to Checkout' to proceed to the final order page. If your institution requires it, you can enter an optional Purchase Order (PO) number here. Review your order and click 'Place an Order'. That's it! We'll take it from here. Your RNA will be synthesized and shipped as quickly as possible. Invoices are sent electronically upon confirmation of delivery, and all invoices are issued on Net30 terms.
PRIME is Cisterna's core RNA production platform, capable of synthesizing all RNA types including mRNA, tRNA, siRNA, sgRNA, aptamers, and more. The PRIME platform is engineered to drastically reduce product-related impurities such as dsRNA, short-truncated products, abortive transcripts, and DNA:RNA hybrids, all commonly generated in standard in vitro transcription. The result is consistently high-quality RNAs that are fully functional and well-suited for most downstream applications such as X-ray crystallography, Cryo-EM, tRNA aminoacylation and protein expression.
Both PRIME and SPECC reflect Cisterna’s commitment to producing high-quality RNA, but they are designed to serve different needs. PRIME is Cisterna’s standard production platform and is applicable to all RNA types. It delivers high-purity RNA suitable for a wide range of applications, from structural and biochemical studies to robust protein expression. For most research applications, PRIME offers excellent performance and exceptional value at an affordable price point. SPECC (SPEcific Capture and Cleavage) is Cisterna’s flagship purification system and is currently available for mRNA only. It takes purity a step further by selectively isolating full-length mRNA transcripts, enabling near-HPLC-level purity. SPECC is the ideal choice when the highest possible mRNA quality is desired, such as in rigorous quantitative studies, high-dose applications, or therapeutic development.